Filing Details
- Accession Number:
- 0000950170-24-121102
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-05 09:04:36
- Reporting Period:
- 2024-11-01
- Accepted Time:
- 2024-11-05 09:04:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779805 | Jonathan Young | C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94941 | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-01 | 40,716 | $21.09 | 267,002 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-01 | 34,943 | $31.25 | 232,059 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-01 | 15,481 | $32.27 | 216,578 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-01 | 292 | $32.94 | 216,286 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-01 | 40,716 | $0.00 | 0 | $21.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2029-12-12 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 20,000 | Indirect | By EA Irrevocable Trust |
| Common Stock | 20,000 | Indirect | By CM Irrevocable Trust |
| Common Stock | 20,000 | Indirect | By JL Irrevocable Trust |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2024, previously adopted by the Reporting Person.
- These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.91, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.92 to $32.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.93 to $32.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3.
- The options are vested and currently exercisable.
Billionaire Hedge Funds
